Deutsche Bank AG reaffirmed their buy rating on shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in a report published on Thursday morning. Deutsche Bank AG currently has a $79.00 price objective on the stock.
A number of other equities analysts have also commented on NBIX. BMO Capital Markets raised their price objective on shares of Neurocrine Biosciences from $83.00 to $109.00 and gave the stock an outperform rating in a research note on Thursday. Leerink Swann reissued an outperform rating and set a $83.00 target price (up previously from $72.00) on shares of Neurocrine Biosciences in a research note on Thursday. Citigroup Inc. restated a buy rating and set a $79.00 price target on shares of Neurocrine Biosciences in a report on Thursday. Piper Jaffray Companies restated a buy rating and set a $76.00 price target on shares of Neurocrine Biosciences in a report on Wednesday, October 25th. Finally, Jefferies Group LLC reiterated a buy rating and issued a $69.00 target price (up previously from $66.00) on shares of Neurocrine Biosciences in a report on Tuesday, October 3rd. One investment analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $78.88.
Shares of Neurocrine Biosciences (NASDAQ:NBIX) traded up $1.03 during midday trading on Thursday, reaching $74.51. 1,081,484 shares of the company’s stock were exchanged, compared to its average volume of 1,079,281. The company has a current ratio of 14.38, a quick ratio of 14.37 and a debt-to-equity ratio of 1.05. Neurocrine Biosciences has a 1 year low of $37.35 and a 1 year high of $63.77.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.49) by $0.36. The company had revenue of $60.77 million for the quarter, compared to analyst estimates of $29.38 million. During the same quarter in the prior year, the business earned ($0.43) EPS. analysts anticipate that Neurocrine Biosciences will post -1.88 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This news story was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.com-unik.info/2017/11/06/deutsche-bank-ag-reaffirms-buy-rating-for-neurocrine-biosciences-inc-nbix.html.
In related news, insider Haig P. Bozigian sold 26,250 shares of Neurocrine Biosciences stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $1,575,000.00. Following the sale, the insider now directly owns 144,601 shares in the company, valued at approximately $8,676,060. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Christopher Flint Obrien sold 6,925 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $61.04, for a total transaction of $422,702.00. Following the sale, the insider now owns 55,898 shares in the company, valued at $3,412,013.92. The disclosure for this sale can be found here. Insiders have sold 101,346 shares of company stock worth $5,879,150 over the last quarter. Corporate insiders own 4.80% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC bought a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at $246,888,000. BlackRock Inc. boosted its holdings in Neurocrine Biosciences by 14,216.0% during the 1st quarter. BlackRock Inc. now owns 5,031,933 shares of the company’s stock worth $217,884,000 after acquiring an additional 4,996,784 shares during the last quarter. TimesSquare Capital Management LLC boosted its holdings in Neurocrine Biosciences by 299.4% during the 2nd quarter. TimesSquare Capital Management LLC now owns 2,315,373 shares of the company’s stock worth $106,507,000 after acquiring an additional 1,735,700 shares during the last quarter. HealthCor Management L.P. boosted its holdings in Neurocrine Biosciences by 108.2% during the 2nd quarter. HealthCor Management L.P. now owns 2,550,178 shares of the company’s stock worth $117,308,000 after acquiring an additional 1,325,178 shares during the last quarter. Finally, FMR LLC boosted its holdings in Neurocrine Biosciences by 9.8% during the 2nd quarter. FMR LLC now owns 13,211,023 shares of the company’s stock worth $607,707,000 after acquiring an additional 1,180,874 shares during the last quarter.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
What are top analysts saying about Neurocrine Biosciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Neurocrine Biosciences Inc. and related companies.